Avrukibart vs picankibart

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Psoriasis

Shared mechanism: IL-23 p19 · full Psoriasis pipeline

Avrukibart

Developed by Oruka Therapeutics

Phase 2 in Psoriasismonoclonal antibody
Partial signal

NCT07090330 · Phase 2 · active, not recruiting

This was a randomized, double-blind Phase 2 trial with 80 participants. Its primary endpoint was met according to the sponsor's announcement of 2026-04-27. The result comes from the sponsor's announcement and the sources read give no power calculation, so the grade is moderate.

Next expected readout: May 2030 · NCT07449702 (registry estimate)

Reported efficacy

Proportion of Participants Achieving 100% Reduction in PASI Score at Week 16: Primary endpoint PASI 100 at week 16 (interim analysis): 63.5% (40/63) with ORKA-001 vs 1 of 21 with placebo (2026-04-27). (met)

Result source: NCT07090330

picankibart

Marketed by Innovent Biologics

Phase 3 in Psoriasismonoclonal antibody (anti-IL-23p19)
Reliable signal

NCT05645627 · Phase 3 · completed

CLEAR-1 was a randomized, double-blind, placebo-controlled Phase 3 trial in 500 Chinese adults with moderate to severe plaque psoriasis. Patients received picankibart 200 mg or placebo for the first 16 weeks. The two primary endpoints at week 16 were at least 90% improvement in PASI and a clear or almost clear sPGA score. With picankibart, 80.3% reached PASI 90 and 93.5% reached sPGA 0/1, against 2.0% and 13.1% with placebo (p<0.0001 for both), so the trial met both primary endpoints. The response rates come from the peer-reviewed paper in the Journal of the American Academy of Dermatology and the p-values from the company announcement.

Reported efficacy

Percentage of participants with a Psoriasis Area and Severity Index (PASI) 90 Response (Week 56): PASI 90 maintenance at Week 56: 89.3% (100 mg) and 90.1% (200 mg) picankibart-maintenance groups vs 37.7% and 51.7% in the corresponding randomized-withdrawal groups; P < 0.0001 for both comparisons (met)

Result source: NCT06049810

Results for Psoriasis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAvrukibartpicankibart
PASI 75—Not reported—Not posted · NCT05645627
PASI 90—Not reported80.3% vs 2%a+78.3 vs placebowk 16NCT05645627
PASI 100—Not reported—Not posted · NCT05645627
sPGA 0/1—Not reported—Not posted · NCT05645627
DLQI, change—Not reported—Not posted · NCT05645627

PASI 75

Avrukibart
—Not reported
picankibart
—Not posted · NCT05645627

PASI 90

Avrukibart
—Not reported
picankibart
80.3% vs 2%a+78.3 vs placebowk 16NCT05645627

PASI 100

Avrukibart
—Not reported
picankibart
—Not posted · NCT05645627

sPGA 0/1

Avrukibart
—Not reported
picankibart
—Not posted · NCT05645627

DLQI, change

Avrukibart
—Not reported
picankibart
—Not posted · NCT05645627
  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Avrukibart
Primary endpoint PASI 100 at week 16 (interim analysis): 63.5% (40/63) with ORKA-001 vs 1 of 21 with placebo (2026-04-27). NCT07090330 · Phase 2 · design grade: moderate · reviewed ClinicalTrials.gov result

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

picankibart

PASI 90 80.3% vs 2% placebo @ 16wk
responder rate · % of participants
NCT05645627 · Phase 3 · sponsor-reported, not registry data
PASI 90 Response Maintenance 90.1% vs 51.7% corresponding randomized-withdrawal group @ 56wk200 mg picankibart-maintenance
responder rate · % of participants
NCT06049810 · Phase 3 · sponsor-reported, not registry data
show 1 more result
89.3% vs 37.7% corresponding randomized-withdrawal group @ 56wk100 mg picankibart-maintenance
NCT06049810 · Phase 3 · sponsor-reported, not registry data

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Avrukibart's landscape · picankibart's landscape